文献速递姑息放疗与转移瘤放疗物理与技术

0-7-21方案自适应放疗:肿瘤体积反应的回顾性研究

Adaptive Radiation Therapy in the 0-7-21 Regimen: A Retrospective Study of Tumor Volumetric Response.
PubMed 文献 · Adv Radiat Oncol · 2026-05-22

本研究回顾性分析2017年2月至2022年6月接受0-7-21姑息放疗方案的105例患者193个病灶,利用第0天和第21天锥形束CT计算肿瘤体积变化。第0至21天平均体积变化为-9.9%(SD 19.94)。多变量分析显示,Merkel细胞组织学与肿瘤体积缩小相关,吸烟史与肿瘤体积增大相关。

要点

  • 0-7-21方案第0至21天平均肿瘤体积变化为-9.9%(SD 19.94)。

核心结论

  • 在线自适应放疗可能使具有Merkel细胞组织学和吸烟史的特定0-7-21姑息方案患者获益,值得未来研究和资源分配考虑。

研究设计与样本

  • 单机构回顾性研究,纳入2017年2月至2022年6月接受0-7-21方案治疗的患者,收集第0天和第21天锥形束CT的肿瘤总体积,按体积变化百分比四分位分组,行单变量和多变量线性回归分析。

主要发现

  • 共纳入105例患者193个病灶,平均年龄77岁,男性57例(54.3%),非吸烟者42例(40%)。
  • 头颈部原发125个(64.8%),头颈部解剖部位160个(82.9%),鳞状细胞癌148个(76.7%)。
  • 9个病灶(4.7%)在同步全身治疗期间接受治疗。
  • 第0至21天平均体积变化百分比为-9.9%(SD 19.94)。

临床怎么用

  • 对于接受0-7-21姑息放疗方案、具有Merkel细胞组织学和吸烟史的患者,可考虑在线自适应放疗以个体化调整治疗。

局限性

  • 本研究为单机构回顾性研究,样本量有限,结论需未来研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A hypofractionated palliative radiation regimen referred to as "0-7-21," which involves 1500 to 2400 cGy prescribed in 3 fractions delivered over 3 weeks (ie, days 0, 7, and 21), has been well documented in literature as an effective way to alleviate symptoms in solid malignancies with minimal toxicity and logistics. Given the time between fractions, this study aimed to identify predictive factors of on-treatment tumor response in patients treated with the 0-7-21 regimen to help select palliative patients who may benefit from adaptive therapy. METHODS AND MATERIALS: This single-institution retrospective review of patients treated with 0-7-21 from February 2017 to June 2022. Gross tumor volumes from cone-beam computed tomography at days 0 and 21 were collected. The calculated percent change in lesion volume was grouped into quartiles. Groups showing the greatest reduction (25th percentile) versus the greatest growth or least reduction (75th percentile) were analyzed. Univariate and multivariable linear regression models identified factors associated with the percent change in tumor volume. RESULTS: A total of 105 patients with 193 lesions were included. The mean age was 77 years, the majority were men (n = 57, 54.3%), and several were nonsmokers (n = 42, 40%). Head and neck primaries (n = 125, 64.8%), head and neck anatomic sites (n = 160, 82.9%), and squamous cell carcinoma (n = 148, 76.7%) were the most common. Nine lesions (4.7%) were treated during concurrent systemic therapy. From days 0 to 21, the mean percent volume change was -9.9% (SD, 19.94). On multivariable analysis, Merkel cell histology (-24.24% [95% CI, -45.4 to -3.06]; P = .03) and smoking history (6.10 [95% CI, -0.22 to -10.84]; P = .047) were associated with tumor volume reduction and growth, respectively. Merkel cell histology was the only factor associated with the group with the largest volume reduction (25th percentile) on multivariable analysis (odds ratio, 15.34; 95% CI, 1.52-154.41; P = .02). CONCLUSIONS: Online adaptive radiation therapy may benefit selected 0-7-21 palliative regimen patients with Merkel cell histology and a smoking history, warranting consideration in future studies and resource allocation.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chelvarajah RC, Bartolucci DD, Javor J, et al. Adaptive Radiation Therapy in the 0-7-21 Regimen: A Retrospective Study of Tumor Volumetric Response. Adv Radiat Oncol. 2026. PMID: 42382438. doi:10.1016/j.adro.2026.102088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。